chevron_leftBack
As of 15 June 2026, Hinova Pharmaceuticals Inc. has a market cap of $642.96M USD, ranking #13472 globally and #4095 in China.
It ranks #1212 in the Healthcare sector, and #449 in the Drug Manufacturers - General industry.
Key Stats
Market Cap
$642.96MUSD
4.36B CNY
Enterprise Value
$536.98MUSD
3.63B CNY
Revenue (TTM)
$6.86MUSD
46.5M CNY
EBITDA (TTM)
-$21.58MUSD
-146.06M CNY
Net Income (TTM)
-$19.93MUSD
-135.03M CNY
Profit Margin
-290%
PS Ratio
93.7
PB Ratio
4.2
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Yuanwei Chen
open_in_new
Employees
174
Founded
2013
Website
hinovapharma.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| 7.9% | -6.6% | 8.1% | -4.6% | -12% | 15% |
News
Loading...
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
688302
海创药业股份有限公司 Class A
ISIN: CNE1000059F5
Shares Out.:
Shares Outstanding:
72.724M1
Shares Float:
72.71M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
BA:
Barron's:
MS:
Morningstar:
|
44.00 CNY |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About Hinova Pharmaceuticals Inc.
Hinova Pharmaceuticals Inc., a clinical-stage pharmaceutical company, engages in the development and production of therapeutics for cancers and metabolic syndromes. It develops drugs based on proteolysis targeting chimera and deuteration technology. The company’s products pipeline includes HC-1119, a product in phase III clinical trials with castration resistant prostate cancer indications; HP501, a product in phase II clinical trials for the treatment of hyperuricemia and gout; HP558, a product in phase II clinical trials to treat various late-stage cancers; and HP518, an oral PROTAC drug in phase I clinical trials with a focus on to solve the drug resistance of AR-mutated prostate cancer. Hinova Pharmaceuticals Inc. was founded in 2013 and is headquartered in Chengdu, China.
Similar Companies
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
SSE: 600276
|
$53.85B
8K%
364.89B CNY
|
44.9
|
|
SSE: 603259
|
$49.64B
8K%
336.36B CNY
|
17.2
|
|
SHEK: 3692
|
$28.52B
4K%
223.48B HKD
|
35.7
|
|
SHEK: 1801
|
$18.8B
3K%
147.32B HKD
|
162.3
|
|
SSE: 688506
|
$16.51B
2K%
111.89B CNY
|
-
|
|
SHEK: 9926
|
$16.01B
2K%
125.46B HKD
|
-
|
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
NYSE: LLY
|
$761.68B
118K%
|
38.1
|
|
NYSE: JNJ
|
$547.28B
85K%
|
26.4
|
|
NYSE: ABBV
|
$360.63B
56K%
|
97.4
|
|
SIX: RO
|
$321.52B
50K%
256.25B CHF
|
19.9
|
|
LSE: AZN
|
$288.84B
45K%
215.59B GBP
|
27.6
|
|
SIX: NOVN
|
$274.65B
43K%
218.9B CHF
|
20.5
|
chevron_leftBack